ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss

R. Sapir-Pichhadze,1 X. Zhang,1 A. Ferradji,1 A. Madbouly,2 S. Fingerson,2 K. Tinckam,5 H. Gebel,3 H. Cardinal,4 B. Foster.1

1McGill University, Montreal, Canada
2National Marrow Donor Program, Minneapolis
3Emory University Hospital, Atlanta
4CHUM, Montreal, Canada
5University Health Network, Toronto, Canada.

Meeting: 2018 American Transplant Congress

Abstract number: 208

Keywords: Antibodies, Epitopes, Graft survival, Immunogenicity

Session Information

Session Name: Concurrent Session: Kidney Chronic Antibody Mediated Rejection

Session Type: Concurrent Session

Date: Monday, June 4, 2018

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:18pm-3:30pm

Location: Room 4B

Introduction: HLA matching at the epitope level offers new opportunities to identify compatible donors for transplant candidates. HLAMatchmaker deduces B-cell epitope ('eplets' in HLAMatchmaker) mismatches from allele-level donor-recipient HLA types. We hypothesized that antibody verification informs immunogenicity and antibody-verified mismatches confer greater risk for graft loss than all eplet mismatches.

Methods: Using SRTR, we conducted a retrospective cohort study in unsensitized first kidney transplant recipients (KTR) transplanted between Jan. 1, 2000 to Sept. 2, 2015. KTR with multi-organ transplants, primary graft non-function or without allele-level HLA types were excluded. All and antibody-verified eplets (www.Epregistry.com.br) were ascertained from allele-level donor-recipient HLA types imputed from serologic types by the National Marrow Donor Program algorithm. We fit multivariable Cox proportional hazards models to determine the independent association between class I (HLA-A and -B) and II (-DR) eplet mismatches and death-censored graft loss. All-cause graft loss was a secondary endpoint.

Results: A total of 118,382 KTR were included. Hazard ratios (HR) for death-censored graft loss were higher for antibody-verified compared with all eplet mismatches. HR associated with each additional 1, 5, and 10 HLA eplet mismatches for Class I and II are shown in Table 1. Similar trends were observed for all-cause graft loss.

Epitope MM 1 MM

HR (95% CI)

5 MM

HR (95% CI)

10 MM

HR (95% CI)

Class I AbV 1.011 (1.010, 1.013) 1.056 (1.051, 1.067) 1.116 (1.105, 1.138)
Class I All 1.005 (1.004, 1.006) 1.025 (1.020, 1.030) 1.051 (1.041, 1.062)
Class II AbV 1.020 (1.017, 1.022) 1.104 (1.088, 1.115) 1.219 (1.184, 1.243)
Class II All 1.009 (1.007, 1.010) 1.046 (1.035, 1.051) 1.094 (1.072, 1.105)

Conclusion: A quantitatively greater risk of graft loss with larger numbers of antibody-verified compared with all eplet mismatches, suggests that antibody-verified eplets portend greater immune-risk. Whether a cumulative burden of antibody-verified or immunodominant eplet mismatches determines outcomes is unknown.

CITATION INFORMATION: Sapir-Pichhadze R., Zhang X., Ferradji A., Madbouly A., Fingerson S., Tinckam K., Gebel H., Cardinal H., Foster B. Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Sapir-Pichhadze R, Zhang X, Ferradji A, Madbouly A, Fingerson S, Tinckam K, Gebel H, Cardinal H, Foster B. Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss [abstract]. https://atcmeetingabstracts.com/abstract/antibody-verified-eplet-mismatches-as-determinants-of-premature-kidney-transplant-loss/. Accessed May 23, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences